Key facts
- This page summarizes Helen Torley's Form 4 filing for HALOZYME THERAPEUTICS, INC. (HALO).
- 17 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 19 Aug 2026, 20:01.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Sale
Sale
Sale
Sale
Options Exercise
Sale
Sale
Sale
Options Exercise
Sale
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
Footnote F2
Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F3
Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F4
Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F5
Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F6
Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F7
Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F8
Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F9
Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F10
Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F11
Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F12
Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F13
Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.